Welcome to our dedicated page for Kelyniam Global news (Ticker: KLYG), a resource for investors and traders seeking the latest updates and insights on Kelyniam Global stock.
Kelyniam Global Inc. (KLYG) specializes in advanced cranial implant solutions that combine precision engineering with clinical insights. This news hub provides investors and medical professionals with essential updates on the company's technological advancements, regulatory milestones, and market developments.
Access real-time announcements about FDA-cleared innovations, partnership agreements with healthcare systems, and financial performance reports. Our curated collection includes press releases detailing new biocompatible materials, manufacturing process improvements, and clinical trial outcomes relevant to custom prosthetics.
Key updates cover earnings disclosures, intellectual property acquisitions, and strategic collaborations with neurosurgical teams. Bookmark this page to monitor Kelyniam's progress in developing CAD/CAM-engineered implants that enhance surgical precision while reducing hospital costs.
Kelyniam Global (OTC:KLYG), a custom cranial implants manufacturer, reported record financial results for 2024. The company achieved total revenue of $3,328,382, marking a 24.6% increase from $2,672,357 in 2023. Operating income improved significantly to $277,037 from a loss of ($239,166), representing a $515,203 improvement.
The company's EBITDA turned positive at $322,824 compared to a loss of $189,758 in 2023. Key operational achievements included expanding to 15 new hospitals, completing an FDA audit with minor observations, and sponsoring the Skull Base 360 wet lab at the University of Maryland. The company plans to focus on strengthening partnerships, in-licensing products, and pursuing organic growth in 2025, with significant investments planned in sales and business development activities.
Kelyniam Global (KLYG) has announced significant financial achievements for calendar year 2024, including record revenues exceeding $3.3 million, representing at least 25% growth. The company's operating income increased by at least $500,000 compared to 2023.
The company has completed a comprehensive review of legacy and Covid-related matters, which will be reported as Restructuring Costs and Non-cash Compensation in their annual financial statements. Additionally, KLYG is planning to move to the OTCID Basic Market in 2025 and is considering a reverse stock split after their June 2025 shareholders meeting to improve share liquidity.
The company will host an investor presentation on January 29th, 2025, at 2:00 EST in collaboration with GeoInvesting. Kelyniam specializes in rapid production of custom cranial and maxillo-facial prosthetics using advanced medical grade polymers.
Kelyniam Global (OTC: KLYG), a custom cranial implants manufacturer, has completed a private placement of restricted common stock to accredited investors, closing on November 30, 2024. The offering did not include warrants. The company plans to utilize the proceeds to support its 2025 growth objectives, focusing on:
- Enhanced sales and marketing for current and pipeline products
- Regulatory and FDA filing fees for new product launches
- Geographical expansion across US neurology-focused trauma centers
CEO Ross Bjella noted strong performance in the first three quarters and expressed confidence in deploying funds to build scale across distribution channels and geographies in 2025 and beyond.
Kelyniam Global (KLYG) reported strong Q3 2024 financial results, with total revenue reaching $2,492,607, a 43% increase from the previous year. The company's gross margin grew 44% to $1,956,714, while operating profit improved significantly to $273,248 from a loss of ($329,993). EBITDA also turned positive at $349,099 compared to previous year's loss.
The company attributes its success to overnight service, quality focus, new surgeon acquisitions, and effective expense management. Notable developments include increased market acceptance of CustomizedBone™ regenerative implant and NEOS Cranial Loop fixation products.
Kelyniam Global (OTC: KLYG), a custom cranial implant manufacturer, reported strong financial results for the first half of 2024. The company saw significant improvements across key metrics:
- Total revenue increased by 49.01% to $1,709,239
- Gross margin grew 52.7% to $1,330,965
- Operating profit reached $172,093, up from a loss of $229,345
- EBITDA improved to $197,355 from a loss of $204,691
The company attributes this growth to increased sales, efficiency improvements, and reduced expenses. Kelyniam's patented integrated fixation in PEEK implants and CustomizedBone™ hydroxyapatite implants gained market acceptance. The company also held its annual shareholder meeting, participated in industry events, and announced FDA clearance for a partner product.
Kelyniam Global (OTC: KLYG) reported a significant improvement in its Q1 financials for the quarter ending March 31, 2024. Revenue increased by 60.5% to $957,447, while the gross margin rose by 59.0% to $743,719. The company achieved an operating profit of $123,599, a notable turnaround from a loss of $67,978 in the same period last year, largely due to decreased consulting and IT costs. Surgeons and distributors increasingly use Kelyniam's custom cranial and craniofacial implants, contributing to sales momentum from Q4 into Q1. Interest in the CustomizedBone hydroxyapatite osteo-integrative cranial implant is growing, especially for pediatric patients, boosted by the approval of the NEOS Cranial Loop fixation method. The annual Shareholder Meeting will be held on June 24 at 8:30 am Central. Full financial details are available on the company's website.
